Module 11 Study Guide PDF
Document Details
Uploaded by HumorousNephrite7817
Tags
Summary
This document is a study guide on various glucose-lowering medications for diabetes. It examines different drug classes, mechanisms of action (MOA), adverse effects (AEs), contraindications (CI), and further information such as patient care. The document is helpful for learning about treatment options for type 2 diabetes as well as the different considerations to take when prescribing or monitoring treatment for patients.
Full Transcript
FFP ● When/what lab values make this transfusion a consideration in clinical practice? ● Does it need to be crossed and matched? ● What does the APP need to monitor pre and post transfusion? Cryo ● When/what lab values make this transfusion a consideration in clinical practice? ● Does it need to be...
FFP ● When/what lab values make this transfusion a consideration in clinical practice? ● Does it need to be crossed and matched? ● What does the APP need to monitor pre and post transfusion? Cryo ● When/what lab values make this transfusion a consideration in clinical practice? ● Does it need to be crossed and matched? ● What does the APP need to monitor pre and post transfusion? __________________________________________________________________________________________________________ Module 11 Study Guide Drug Metformin Semaglutide “--glutide” Empagliflozin “---Flozin” Glyburide “---ride” Repaglinide “---glinide” Linagliptin “--gliptin” Thiazolinediones pioglitazone acarbose Class Biguanide GLP1 RA SGLT2 Sulfonylureas Glinides DPP4 inhibitors TZDs A-glucosidase inhibitors MOA Decrease hepatic glucose production; improve insulin sensitivity; increase peripheral glucose uptake Mimics GLP1 action; release of insulin/suppress glucagon; delay gastric emptying/suppress appetite Promotes urinary excretion of glucose Enhance insulin secretion “Cousins of sulfonylureas” Same MOA Inhibits DDP4→ increases incretins→ release insulin/suppress glucagon Increase insulin receptor sensitivity; decrease liver glucose production; enhance glucose uptake in muscle cells Slows the absorption of dietary carbs GI: N/V/D; abd pain Vitamin B deficiency GI: N/V/D Pancreatitis GU infections/necrotizing Hypoglycemia Weight gain Hypoglycemia Weight gain Pancreatitis Severe joint pain -weight gain -edema GI: gas; diarrhea AEs (has a diuretic effect so that’s why it’s great for CHF) Lactic acidosis (RFs: eGFR < 30, alcohol, liver dz, acute HF, contrast dye procedures, past hx of acidosis Gallstones Bowel obstruction/worsening gastroparesis AKI BBW–thyroid c cell tumors in rats Medullary thyroid carcinoma fasciitis of the genitals Dehydration Hypotension Leg infection/amputation? DKA (RF: fasting, alcohol, stress, etc.) Sulfa allergy CI eGFR < 30 (if levels falls during time of therapy–cut dose in ½ ) Family hx of medullary thyroid carcinoma and pts w multiple endocrine neoplasia syndrome -hx of UTI -pancreatic disorder -DKA -eGFR <30 -OB 2nd & 3rd tri/breastfeeding Elderly CrCl < 30 Monitor -renal/liver -B12 -A1C Renal A1C A1C Renal Volume status/BP A1c Renal Extra notes Start dose: 500mg QD w largest meal then gradually increase to up to 2,000 mg/day To reduce GI effects: ER, w food, slow titration #1 med for prediabetes (max dose 850 mg BID) **gradual dose titration** Caloric intake reduction/mindful eating Avoid fatty/spicy foods Tirzepatide (mounjaro) = combo of GLP1 + GIP RA Better weight loss and A1C reduction ● ● ● ● ● ● Insulin detemir (Levemir) Insulin glargine (Lantus, Basaglar) Insulin aspart (Novolog) Insulin lispro (Humalog) Humulin or Novolin N (NPH) Humulin or Novolin R (regular) U-100 and U-500 ○ slower onset and longer duration Take with breakfast d/c if starting insulin Heart failure risk -fractures -liver toxic -bladder CA? -CrCl < 30 -elderly -adrenal insufficiency Heart failure BBW–heart failure CKD Cirrhosis IBD Malabsorption syndrome A1c Renal A1c renal/liver Liver A1c A1c Renal Dc if starting insulin Dosed TID with first bite of each meal Cam take Q other day for GI AEs ○ 100 U most common ● Humalog Mix 75/25 and Novolog Mix 70/30 (analogs); Humulin or Novolin 70/30 ● (insulin NPH + regular premixed insulin) ● Which therapies are expected to have the greatest A1c-lowering effect? ○ GLP1-RA ○ Least? ■ DPP4-I ● What is the difference between Ozempic and Rybelsus, since both are semaglutide? ○ Rybelsus is the oral version for T2DM; Ozempic is injectable ● Which non-insulin T2DM therapies are injected by the patient? ○ Dulaglutide ○ Liraglutide ○ Semaglutide ○ Exenatide ○ Lixisenatide ● ● ● ● ● ● ● ○ Tirzepatide Which T2DM therapies can be combined? ○ GLP1-RA + basal insulin ○ Metformin + insulin Which drugs are currently approved for pediatric patients with Type 2 DM? ○ Peds should really be managed by endo unless they don’t have access to one ○ Ages > 10 yrs ■ GLP1-RA (Liraglutide, dulaglutide) ■ SGLT2I (empagliflozin) Which patients need to monitor their BG more frequently? ○ When starting or adjusting dose; changing diet/exercise ○ 4-10x/day for T1DM & T2DM with very intensive insulin therapies Why do patients with CGM still need a monitoring device with test strips to check their BG with a fingerstick glucose? ○ Suspicion CGM may be inaccurate ○ Waiting for CGM to warm up ○ In clinical setting where BG levels are changing rapidly Which type of glucose-lowering medication is usually used for treatment of T2DM for a patient who is pregnant? -insulin (NPH, Lispro, Aspart, Detemir) -insulin resistance increased during 2nd & 3rd trimesters & decreases immediately postpartum What are principles of treating acute hyperglycemia related to DM in the hospitalized patient? ○ Regular or rapid insulin 1 unit for every 50 mg/dl over goal ○ Fasting goal: <140 ○ Random goal: <180 ○ Best to have basal or sliding scale insulin ○ Critical pts should be on insulin gtt w/ BG checks Q hr ■ Never lower BG <110 in critical pts ○ DKA or HHS ■ Fluids first, then IV insulin ■ Correct acidosis ■ Replace K+ Which drugs are typically held? ○ Oral agents–metformin/SGLT2-I ● How is hypoglycemia treated ○ Levels: ■ 1st (54–70) ■ 2nd (<54) ■ 3rd (severe w AMS findings) ○ Conscious patient—rule of 15 ○ Unconscious patient–assess ABCs, IV dextrose, D10 infusion, thiamine IV, glucagon IV or IM, steroids w no response to regular tx Pharmacotherapy for obesity ● What are the pharmacotherapeutic options? ○ Phentermine-Topiramate (Qsymia)--has an anti seizure med in it ■ Teratogenic ■ Paresthesia ■ Dry mouth, constipation ■ Tachy; HTN ■ Neuropsych effects ■ Metabolic acidosis ○ Phentermine (Adipex-P) ■ Tachy; HTN ■ Dry mouth, HA, insomnia, restlessness ○ Bupropion-Naltrexone (Contrave)--avoid for pts on opioids bc naltrexone is an antagonist ■ BBW: suicidality ■ Dry mouth, N/V/D/C, HA ■ Neuropsych effects ○ Orlistat (Xenical/Alli) ■ GI: oily spotting, gas with discharge, fecal urgency, incontinence ■ Increased risk of kidney stones ○ Liraglutide (Saxenda) ■ N/V/D; pancreatitis, gallbladder dz; gastroparesis; dehydration; tachycardia ■ BBW: medullary thyroid cancer/multiple endocrine neoplasia type 2 ■ Suicidal ideation ○ Semaglutide (Wegovy) ■ Same as above ● Which obesity medication is available over the counter? ○ Orlistat ● Which medication is only approved for short-term use? ○ Phentermine→ max 12 wks→ schedule IV med for abuse